在生物科技供应链中打造韧性与效率

非结构化数据不仅带来不便，更是导致供应链关键漏洞的根源，严重削弱了效率、可靠性和韧性。本文揭示了非结构化数据在现代供应链中隐藏的陷阱、其对生物科技行业的影响，以及知识管理平台所发挥的关键作用。

供应链的隐形破坏者

高效的供应链使企业能够优化生产力并紧跟不断变化的市场趋势。当关键业务建立在不稳定的数据基础之上时，会发生什么？非结构化数据会造成信息缺口和差异，并波及整个供应链。这可能导致：

市场预测不可靠及资源分配失当—数据不一致和缺失会导致预测分析出现偏差，从而阻碍战略决策、主动库存调整和生产优化。
利益相关者沟通碎片化及运营中断—数据差异会损害供应链上下游的一致性，导致协调不力、中断风险增加以及代价高昂的延误。
可追溯性差及合规风险增加—非标准化的数据格式会导致文档记录不一致，从而引发潜在的安全问题、产品召回以及严重的法律处罚，进而损害声誉和市场影响力。

尽管非结构化数据是一个普遍存在的问题，但在复杂的供应链中，其后果会变得更加严重。‍

非结构化数据放大了生物科技供应链的脆弱性

‍在生物科技供应链中，独特的复杂性放大了非结构化数据的影响，威胁到治疗药物的交付、患者安全以及改变生命的治疗管线的完整性。


Wide market and demand volatility. Unpredictable spikes in vaccines, biologics, and other therapeutics demand stress supply chain flexibility, impacting production and delivery time.
Unstructured data impact: Inaccurate market forecasting Delayed inventory adjustments Sub-optimal production planning	Real life example: The global demand for COVID-19 vaccines caused unprecedented bioprocessing expansion, straining supply chains with availability issues and delivery delays.
Active Pharmaceutical Ingredient (API) sourcing and shortages. Unstable geopolitical climates and global regulatory shifts exacerbate API sourcing challenges, increasing the risk of shortages and impacting production.
Unstructured data impact: Hinders feedstock replacement and prediction analysis Disrupts and limits API procurement strategy	Real life example: The recent U.S. Biosecure Act, restricting engagement with certain Chinese firms until 2032, urges U.S. biotech companies to quickly identify API domestic suppliers to avoid costly supply chain disruptions.
Stakeholder interdependencies and miscommunication. Ineffective coordination among stakeholders can lead to delays in production and therapy approval, jeopardizing the timely delivery of life-changing treatments to patients in need.
Unstructured data impact: Disrupts communication among key stakeholders across the supply chain Exacerbates delays in the time-to-patient delivery of critical therapeutics	Real life example: In Canada, fragmented coordination among regulatory bodies, health assessment agencies, and funding organizations has caused critical delays, denying cancer patients timely access to life-saving treatments
High-stakes cold chain logistics and breaches. Imprecise or unreliable tracking systems in complex cold chains can compromise temperature-sensitive shipment integrity, safety, and compliance.
Unstructured data impact: Decreased traceability Increased risk of mishandling and degradation of sensitive goods (i.e. patient samples, proprietary compounds)	Real life example: In 2022, the UK Health Security Agency reported that vaccine wastage accounted for £5.7 million of NHS funds, with 50% of the reported wastage due to cold chain breaches
Complex regulatory landscape and Changing Guidelines. Ever-evolving regulatory guidelines create reporting complexities that can disrupt supply chain operations, delay product approvals, and impact market entry timelines.
Unstructured data impact: Limited operational visibility and data accessibility Delays in information retrieval required for regulatory approval and market entry	Real life example: The 2022 EU's Clinical Trials Regulation (CTR) urged biotech companies to quickly adapt to new submission processes and compliance standards to prevent delays in clinical trial applications.

Wide market and demand volatility. Unpredictable spikes in vaccines, biologics, and other therapeutics demand stress supply chain flexibility, impacting production and delivery time.

Unstructured data impact:

Inaccurate market forecasting

Delayed inventory adjustments

Sub-optimal production planning

Real life example:

The global demand for COVID-19 vaccines caused unprecedented bioprocessing expansion, straining supply chains with availability issues and delivery delays.

Active Pharmaceutical Ingredient (API) sourcing and shortages. Unstable geopolitical climates and global regulatory shifts exacerbate API sourcing challenges, increasing the risk of shortages and impacting production.

Unstructured data impact:

Hinders feedstock replacement and prediction analysis

Disrupts and limits API procurement strategy

Real life example:

The recent U.S. Biosecure Act, restricting engagement with certain Chinese firms until 2032, urges U.S. biotech companies to quickly identify API domestic suppliers to avoid costly supply chain disruptions.

Stakeholder interdependencies and miscommunication. Ineffective coordination among stakeholders can lead to delays in production and therapy approval, jeopardizing the timely delivery of life-changing treatments to patients in need.

Unstructured data impact:

Disrupts communication among key stakeholders across the supply chain

Exacerbates delays in the time-to-patient delivery of critical therapeutics

Real life example:

In Canada, fragmented coordination among regulatory bodies, health assessment agencies, and funding organizations has caused critical delays, denying cancer patients timely access to life-saving treatments

High-stakes cold chain logistics and breaches. Imprecise or unreliable tracking systems in complex cold chains can compromise temperature-sensitive shipment integrity, safety, and compliance.

Unstructured data impact:

Decreased traceability

Increased risk of mishandling and degradation of sensitive goods (i.e. patient samples, proprietary compounds)

Real life example: In 2022, the UK Health Security Agency reported that vaccine wastage accounted for £5.7 million of NHS funds, with 50% of the reported wastage due to cold chain breaches

Complex regulatory landscape and Changing Guidelines. Ever-evolving regulatory guidelines create reporting complexities that can disrupt supply chain operations, delay product approvals, and impact market entry timelines.

Unstructured data impact:

Limited operational visibility and data accessibility

Delays in information retrieval required for regulatory approval and market entry

Real life example: The 2022 EU's Clinical Trials Regulation (CTR) urged biotech companies to quickly adapt to new submission processes and compliance standards to prevent delays in clinical trial applications.

这些挑战的综合影响波及日常运营，并降低了生物科技供应链的整体韧性。通过实施稳健的数据管理策略，企业可以加强其供应链，从而更好地应对这些挑战并提高效率。

数据管理平台的收益

‍高效的供应链依赖于结构化且可靠的数据。实施有效的数据管理平台，使企业能够将分散、非结构化的信息转化为强大的资源，从而简化决策流程、提升运营效率并降低风险。借助合适的数据管理解决方案，企业可以获得以下优势：

个性化见解，增强供应链韧性： 通过全面的供应链分析，企业能够精准定位采购流程中的薄弱环节，寻找高风险原材料或供应商的替代方案，并降低中断风险。

通过实施供应链运作参考（SCOR）模型，罗氏制药技术开发临床供应链团队实现了准时交付率 95% 的提升，并将按单生产成品套件的交付周期缩短了 50%，从而显著提高了临床供应运营的效率和可靠性。

‍实时数据采集，提升可追溯性：通过集成实时数据采集系统，企业可以促进复杂供应链的持续监控，确保精准追踪并最大限度地减少中断。

简化沟通，实现高效协作：通过采用基于云的系统，企业可以在内部各部门之间以及与外部合作伙伴之间促进安全的数据交换，从而简化协作与运营。

In its digital transformation efforts, Novartis partnered with Amazon Web Services to develop a multi-cloud data platform, facilitating data sharing, collaboration, and operational efficiency across various business functions, including supply chains and procurement.

Read more

‍

高级检索功能，简化数据获取：将定制检索工具和索引技术集成到数据管理平台中，可简化数据获取流程，从而实现无缝的报告生成、审计追踪和监管提交。

By adopting a custom knowledge management system, a health-tech organization transformed decades of unstructured data into a strategic asset, reducing data retrieval times from hours to just minutes.

Download the success story

对于生物科技行业而言，采用先进的数据管理解决方案不仅是为了提高运营效率，更是为了巩固能够改变生命的治疗药物研发管线。高效的数据流程使生物科技公司能够通过识别高风险材料和供应商来降低短缺风险，同时基于可靠的市场预测主动优化库存。通过实时可追溯性、云端交换和简化的监管提交，数据管理已成为生物科技行业的基石，它能保护复杂管线中的敏感材料，从而更快地将治疗药物交付给患者。

As an international leader in chemical logistics, Rinchem combined real-time data collection systems with human-curated regulatory data to ensure 24/7 visibility and compliance across its global supply chain.

Read more

‍忽视数据风险已不再是选项

‍在当今数据驱动的环境中，忽视非结构化数据带来的挑战已不再可行。拥抱稳健知识管理战略的领导者，不仅能够帮助其组织降低脆弱性，还能为实现卓越运营解锁新的机遇。通过实施适用于贵单位生物科技供应链的数据管理平台，您可以将潜在的信息陷阱转化为无与伦比的驱动力，从而提升效率、确立市场领导地位并实现改变生命的突破。
‍
了解更多关于 CAS 如何帮助解决与非结构化数据相关的挑战 探索 CAS Custom ServicesSM^SM